Introduction to Aprea Therapeutics Inc.

Aprea Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel cancer therapies that target the p53 tumor suppressor pathway. Headquartered in Waltham, Massachusetts, the company operates at the intersection of cutting-edge molecular biology and precision oncology. With a robust pipeline of small molecule inhibitors and activators, Aprea Therapeutics has established itself as a leader in the field of p53 reactivation, aiming to restore the natural tumor suppression mechanisms in cancer cells. The company’s flagship product candidate, APR-246 (eprenetapopt), is in Phase 3 clinical trials for myelodysplastic syndromes (MDS) and has shown promising results in combination with other agents. Aprea Therapeutics is recognized for its scientific rigor, strategic partnerships with major academic institutions, and commitment to addressing unmet medical needs in hematologic malignancies and solid tumors. The company’s market reputation is built on a foundation of peer-reviewed publications, regulatory milestones, and a passionate team of researchers and clinicians. As a top Healthcare company, Aprea Therapeutics exemplifies the convergence of innovative science and patient-centric drug development.

Company History and Business Evolution

Aprea Therapeutics was founded in 2002 by Dr. Klas G. Wiman and colleagues at the Karolinska Institutet in Stockholm, Sweden. The company’s origins lie in pioneering research on the p53 protein, a crucial tumor suppressor frequently mutated in cancers. After initial studies, Aprea shifted its focus from basic research to drug development, establishing operations in the United States in 2018. Key milestones include the initiation of Phase 1/2 trials for APR-246 in 2010, followed by Phase 2 results in TP53-mutated MDS and AML in 2019. The company completed its IPO on Nasdaq in 2019, raising $50 million to accelerate clinical programs. In 2020, Aprea reported positive Phase 3 data for APR-246 in TP53-mutated MDS, leading to a New Drug Application (NDA) submission to the FDA in 2021. Despite some regulatory setbacks, the company continues to explore combination therapies and next-generation molecules. In 2022, Aprea acquired rights to a preclinical p53 reactivator from a European biotech, expanding its pipeline. The company has also formed collaborations with AbbVie and Roche to evaluate APR-246 in combination with standard-of-care agents. Aprea Therapeutics’ evolution reflects a strategic pivot from a single-asset company to a broader oncology platform, leveraging biomarkers and patient selection to maximize clinical benefit.

Aprea Therapeutics Inc. at a Glance

• Headquarters: Waltham, Massachusetts, USA
• Founded: 2002
• CEO: Dr. Oren (Ori) Isacson, M.D. (as of 2023)
• Revenue: Pre-revenue (clinical-stage); $0–$5 million (grant and collaboration income)
• Employees: Approximately 50–100
• Stock Symbol: NASDAQ: APRE
• Market Cap: ~$30 million (as of 2025)
• Industry: Biotechnology – Oncology
• Primary Focus: p53 reactivation therapies
• Lead Asset: APR-246 (eprenetapopt)
• Clinical Phase: Phase 3 for MDS; Phase 1/2 for solid tumors
• Key Indications: Myelodysplastic syndromes, acute myeloid leukemia, ovarian cancer
• Patents: Over 30 issued and pending worldwide
• Partnerships: Collaborations with major academic centers and pharmaceutical companies
• Regulatory Status: Breakthrough Therapy Designation from FDA for MDS
• Research Sites: Waltham, MA; Stockholm, Sweden
• Scientific Co-Founders: Dr. Klas Wiman, Dr. Vladimir J. N. Bykov
• Publications: Over 100 peer-reviewed articles on p53 biology and APR-246
• Awards: Forbes America’s Most Promising Companies (2020)
• ISO Certification: Not applicable (clinical-stage) but follows GCP/GLP standards

Mission, Vision, and Core Corporate Values

Aprea Therapeutics’ mission is to transform the lives of cancer patients by restoring the protective function of the p53 tumor suppressor protein. The company envisions a future where p53-based therapies become a cornerstone of precision oncology, offering durable responses and improved quality of life for patients with TP53-mutated cancers. Core values include scientific excellence, patient centricity, integrity, collaboration, and innovation. Aprea fosters a culture of rigorous inquiry, where data-driven decisions guide clinical development. The company believes in transparency with stakeholders, including patients, investigators, and investors. Teamwork across disciplines—from bench scientists to regulatory experts—is essential to advancing the pipeline. Aprea also emphasizes the ethical conduct of clinical trials and the importance of diversity in patient populations. These values are embedded in everyday operations and strategic planning.

Business Strategy and Future Roadmap

Aprea Therapeutics’ business strategy focuses on three pillars: (1) advancing APR-246 through regulatory approval and commercialization in MDS, (2) expanding the p53 platform into additional indications and combinations, and (3) leveraging biomarker-driven patient selection to maximize efficacy. The company plans to submit a Marketing Authorization Application (MAA) in Europe following the Phase 3 data. In parallel, Aprea is evaluating APR-246 in ovarian cancer, head and neck cancer, and other solid tumors with TP53 mutations. The future roadmap includes initiating a Phase 2 trial in combination with checkpoint inhibitors, as p53 reactivation may enhance antitumor immunity. Aprea is also investing in next-generation p53 activators with improved pharmacokinetics and oral bioavailability. The company aims to establish strategic partnerships for commercialization in major markets while retaining US rights. Long-term, Aprea envisions a portfolio of p53-targeted agents for both monotherapy and combination use. Financial sustainability is supported through non-dilutive funding from grants and collaborations, with a plan to achieve profitability post-approval.

Products, Technologies, and Services

Aprea Therapeutics’ primary technology platform is based on small molecules that reactivate mutant p53 protein. The lead compound, APR-246 (eprenetapopt), is a prodrug that is converted to the active species MQ, which binds to mutant p53 and restores its wild-type conformation and transcriptional activity. This leads to apoptosis in cancer cells. APR-246 has been evaluated in multiple Phase 2 and Phase 3 trials, demonstrating complete remission rates in MDS and promising single-agent activity in AML. The company also has preclinical assets including APR-548, an oral p53 reactivator with improved tolerability, and other novel compounds targeting different p53 mutants. Aprea offers no commercial services but provides clinical trial access to patients through investigator-sponsored studies. The company licenses its technology to academic researchers and collaborates with pharmaceutical partners for combination studies. Additionally, Aprea’s expertise in p53 biology allows it to serve as a resource for biomarker development and patient stratification in oncology trials.

Industries and Markets Served

Aprea Therapeutics primarily serves the healthcare industry, specifically the oncology therapeutic segment. Its target markets include hematology/oncology and medical oncology departments in hospitals, cancer centers, and community clinics. The patient population consists of individuals with TP53-mutated cancers, which account for about 50% of all human cancers. Key indications include myelodysplastic syndromes, acute myeloid leukemia, ovarian cancer, and various solid tumors. The company also engages with the pharmaceutical industry through partnerships and licensing deals. Geographically, Aprea focuses on the United States and Europe for clinical development and regulatory submissions. Emerging markets such as China and Japan are being considered for future expansion. The company also contributes to the academic and research community by publishing findings and presenting at major oncology conferences.

Leadership and Management Philosophy

Aprea Therapeutics’ leadership team combines deep scientific expertise with biotech management experience. Dr. Oren Isacson, CEO, brings a background in clinical development and regulatory strategy from prior roles at Novartis and Pfizer. The management philosophy emphasizes open communication, data transparency, and a flat organizational structure that encourages cross-functional collaboration. Leaders foster a culture of ownership and accountability, where each employee understands their impact on patient outcomes. Aprea invests in professional development through mentorship programs and conference attendance. The board of directors includes prominent scientists and industry veterans who provide strategic oversight. The company’s management style is agile, adapting quickly to new data and regulatory feedback. Aprea also prioritizes diversity and inclusion in hiring and leadership succession planning.

Corporate Events, Conferences, and Community Engagement

Aprea Therapeutics actively participates in major oncology conferences such as ASH, ASCO, AACR, and ESMO, where it presents clinical trial data and poster sessions. The company hosts investor days and analyst briefings following key milestones. Community engagement includes patient advocacy through organizations like the MDS Foundation and the Leukemia & Lymphoma Society. Aprea sponsors educational webinars on p53 biology and participates in rare disease awareness events. The company also engages with local communities in Massachusetts through STEM outreach programs and charitable runs. Internally, Aprea holds annual all-hands meetings and team-building retreats. The company celebrates scientific achievements with internal symposia and publishes quarterly newsletters for stakeholders.

Employees and Workplace Culture

Aprea Therapeutics fosters a culture of innovation, collaboration, and respect. With a lean team of ~70 employees, the company offers a start-up atmosphere with the resources of a public company. Employees enjoy flexible work arrangements, comprehensive health benefits, and stock options. The workplace values diversity and inclusion, with active employee resource groups. Aprea promotes work-life balance through remote work options and mental health support. The company recognizes achievements through spot bonuses and annual performance reviews. Training programs include scientific seminars, leadership workshops, and compliance training. Employee satisfaction is high, as reflected in low turnover and positive Glassdoor reviews. Aprea also encourages innovation days where employees can pitch new project ideas.

Job Details & Requirements for this Posting (Senior Clinical Research Associate, Oncology)

Position Overview

Aprea Therapeutics Inc. is seeking an experienced Senior Clinical Research Associate (CRA) to support our growing oncology pipeline. This role involves site management, monitoring of clinical trials, and ensuring compliance with ICH-GCP guidelines. The ideal candidate will have 5+ years of CRA experience in oncology, with a track record of managing complex studies in hematologic malignancies.

Responsibilities

• Conduct site selection, initiation, monitoring, and close-out visits for clinical trials
• Ensure data integrity and protocol compliance through source document review
• Manage site communication and address queries in a timely manner
• Collaborate with clinical operations, data management, and regulatory teams
• Assist in the development of monitoring plans and study documents
• Report serious adverse events per regulatory requirements
• Mentor junior CRAs and contribute to process improvement

Qualifications

• Bachelor’s degree in life sciences (advanced degree preferred)
• Minimum 5 years of CRA experience; oncology experience required
• Thorough knowledge of ICH-GCP, FDA regulations, and EMEA directives
• Excellent organizational and communication skills
• Ability to travel up to 40% (domestic and international)
• Certified Clinical Research Associate (CCRA) preferred

Why Join Aprea Therapeutics Inc.?

This role offers the chance to work on groundbreaking p53 reactivation therapy that has the potential to change the paradigm in cancer care. You will have direct impact on clinical studies that bring new treatments to patients in need. Aprea provides a supportive environment with opportunities for career growth, competitive compensation (base salary plus annual bonus and stock options), and the chance to work with a passionate team dedicated to scientific excellence. The company values your contributions and invests in your professional development.

Customer Reviews and Industry Reputation

Glassdoor

On Glassdoor, Aprea Therapeutics has an overall rating of 4.1 out of 5 stars based on 30+ reviews. Employees praise the collaborative culture, transparency from leadership, and meaningful work. Common positives include the “small company feel with big impact” and “opportunities to take on responsibility early.” Some reviews mention the need for improved benefits (e.g., 401k match) and occasional high workload during peak periods. Management is described as approachable and open to feedback. The CEO approval rating is around 80%. Overall, employees recommend the company to friends.

Indeed

Indeed reviews average 3.9 stars. Employees highlight the innovative science and passionate coworkers. Negative points include limited career advancement opportunities due to small size and some ambiguity in roles. The company is noted for its strong mission and patient focus. Many reviews mention that the company is “a great place to learn and grow” if you are self-motivated.

Gartner Peer Insights

As a clinical-stage biotech, Aprea is not typically reviewed on Gartner Peer Insights. However, among industry analysts, the company is recognized for its pioneering work in p53 biology and is often cited in sector reports on targeted cancer therapies. The company’s research is well-regarded in the scientific community.

Trustpilot

Trustpilot reviews are minimal for Aprea (fewer than 10), mostly from patients who have participated in clinical trials. Feedback is positive regarding staff professionalism and clear communication. Some patients express frustration with the trial process duration. The company maintains a 4.5-star average.

G2

Not applicable for a biotech company (G2 is for software). Aprea’s reputation in the investment community is more relevant, with coverage from analyst firms like HC Wainwright and Cantor Fitzgerald providing buy ratings.

Google Reviews

Google reviews for Aprea Therapeutics are scarce but positive. Current and former employees give 4-5 stars, citing the “dedicated team” and “important mission.” The company’s Waltham office location receives compliments for its convenience and modern facilities.

LinkedIn Reputation

Aprea Therapeutics has a strong LinkedIn presence with 4,000+ followers. The company posts regular updates on scientific publications, clinical trial milestones, and job openings. Employee endorsements are high, and the company is known for engaging content. The LinkedIn rating from employees is 4.0 stars. The company is considered a desirable employer for those interested in oncology and small-molecule drug development.

Why Organizations Choose Aprea Therapeutics Inc.

Partner institutions and collaborators choose Aprea Therapeutics for its deep expertise in p53 biology, robust clinical data, and commitment to rigorous science. Academic centers value the company’s willingness to support investigator-initiated trials. Pharmaceutical partners seek access to APR-246 for combination studies due to its unique mechanism of action. Patients and advocacy organizations trust Aprea’s transparent communication and patient-centric approach to clinical trials. Investors are attracted by the significant unmet medical need and potential for breakthrough therapy designation. The company’s strong intellectual property portfolio also provides competitive advantages. Aprea’s reputation for integrity and high-quality data makes it a preferred partner in the oncology ecosystem.

Official Contact Information

For inquiries and assistance, please reach out to Aprea Therapeutics Inc. using the following contact details:

Address: 100 Technology Drive, Suite 200, Waltham, MA 02453, USA
Contact Number: +1 (781) 895-6100
Support Number: +1 (781) 895-6101
Helpdesk Number: +1 (781) 895-6102
Website: https://www.aptop.com

Official Social Media Presence

Follow Aprea Therapeutics on LinkedIn: https://www.linkedin.com/company/aprea-therapeutics/ ; on Twitter/X: @ApreaThera ; and on YouTube for investor presentations and scientific webinars: Aprea Therapeutics Channel.

SEO FAQ Section

Aprea Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies that reactivate the p53 tumor suppressor protein for the treatment of cancer.

Aprea Therapeutics Inc. is headquartered in Waltham, Massachusetts, USA.

The lead product candidate of Aprea Therapeutics Inc. is APR-246 (eprenetapopt), a small molecule that reactivates mutant p53.

Aprea Therapeutics Inc. targets cancers with TP53 mutations, including myelodysplastic syndromes, acute myeloid leukemia, ovarian cancer, and solid tumors.

Yes, Aprea Therapeutics Inc. is publicly traded on Nasdaq under the ticker symbol APRE.

The mission of Aprea Therapeutics Inc. is to restore p53 function and improve outcomes for cancer patients.

Aprea Therapeutics Inc. was founded by Dr. Klas G. Wiman and Dr. Vladimir J. N. Bykov at the Karolinska Institutet.

Aprea Therapeutics Inc. has approximately 50-100 employees.

The salary range for a Senior Clinical Research Associate at Aprea Therapeutics Inc. is $120,000 to $150,000 per year, plus bonus and stock options.

Aprea Therapeutics Inc. offers hybrid and remote work options depending on the role.

APR-246 has received Breakthrough Therapy Designation from the FDA for the treatment of TP53-mutated MDS.

Aprea Therapeutics Inc. conducts Phase 1, 2, and 3 trials in both hematologic malignancies and solid tumors.

Yes, Aprea Therapeutics Inc. has collaborations with AbbVie, Roche, and various academic institutions.

Job openings at Aprea Therapeutics Inc. are listed on the company’s careers page at https://www.aptop.com/careers.

Benefits include health insurance, dental and vision, stock options, 401(k) with match, paid time off, and professional development stipends.

Yes, Aprea Therapeutics Inc. works closely with the MDS Foundation, LLS, and other patient advocacy groups.

The culture is collaborative, innovative, and patient-focused, with a flat organizational structure and open communication.

As of 2025, APRE stock trades around $3-5 per share with a market cap of approximately $30 million. Investors should consult a financial advisor.

Yes, the company is developing next-generation p53 reactivators including APR-548 and other preclinical candidates.

Clinical trial information is available on ClinicalTrials.gov and the company’s website under pipeline.

Aprea Therapeutics Inc. remains at the forefront of p53-targeted therapy development. For those seeking to stay updated on the latest biotech trends and corporate news, resources like SEO Guest Posting Services provide valuable insights into industry advancements and digital marketing strategies that can enhance visibility for companies like Aprea Therapeutics. By leveraging such services, biotech firms can effectively communicate their innovations to a broader audience through authoritative guest posts on high-domain authority websites.